AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00068393
Drug: G-CSF (granulocyte-colony stimulating factor)
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
Trial: NCT00068393
Drug: Neulasta
RxNorm normalized name: Neulasta
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
Trial: NCT02636231
Drug: Endostatins
RxNorm normalized name: Endostatins
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
Trial: NCT00915408
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
Trial: NCT00915408
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
Trial: NCT00990392
Drug: Polysporin Triple Therapy ointment
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
Trial: NCT00004787
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04068272
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eyedrop
Trial: NCT00679029
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00679029
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02737800
Drug: GnRh agonist ( Decapeptyl )
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 monthly doses of Decapeptyl 7.5mg intramuscular
Trial: NCT01976650
Drug: dexamethasone 700 ㎍ intravitreal implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
Trial: NCT02178059
Drug: terbutaline sulphate delivered dose
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg terbutaline sulphate (delivered dose) per inhalation
Trial: NCT02178059
Drug: terbutaline sulphate metered dose
RxNorm normalized name: terbutaline Metered Dose Inhaler
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg terbutaline sulphate (metered dose) per inhalation
Trial: NCT01989416
Drug: 2% chlorhexidine wipe
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ICU patients will be bathing with 2% chlorhexidine wipe
Trial: NCT03494231
Drug: HLX06
RxNorm normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
Trial: NCT00652626
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01431690
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 25 mg dose of warfarin
Trial: NCT01431690
Drug: omega-3-acid ethyl esters
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 1 g capsule dose of Lovaza®
Trial: NCT04571437
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole daily alone
Trial: NCT04197622
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
Trial: NCT02568020
Drug: keto-amino acids
RxNorm normalized name: Keto-C
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
Trial: NCT02926586
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
Trial: NCT02926586
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
Trial: NCT01167738
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/mq on days 1 and 15 every 4 weeks
Trial: NCT01167738
Drug: epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/mq on days 1 and 15 every 4 weeks
Trial: NCT01167738
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/mq on days 1 and 15 every 4 weeks
Trial: NCT02218827
Drug: Loteprednol Etabonate (FML)
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
Trial: NCT00836082
Drug: PF-04457845, FAAH inhibitor
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of 0.5mg given once daily for 14 days.
Trial: NCT01167738
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 g days 1-28 every 4 weeks
Trial: NCT03428633
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paravertebral block using ropivacaine preoperatively and postoperatively
Trial: NCT03428633
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine intraoperatively and postoperatively
Trial: NCT00836082
Drug: PF-04457845, FAAH inhibitor
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of 1mg given once daily for 14 days.
Trial: NCT00836082
Drug: PF-04457845, FAAH inhibitor
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
Trial: NCT03691207
Drug: AL101
RxNorm normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously
Trial: NCT00836082
Drug: PF-04457845, FAAH inhibitor
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
Trial: NCT00836082
Drug: PF-04457845, FAAH inhibitor
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
Trial: NCT01058993
Drug: AMD3100 or plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
Trial: NCT01736397
Drug: Ferric Citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sulfate (DB11171)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose depends on serum phosphorus levels collected at each study visit.
Trial: NCT03652571
Drug: Nortriptyline
RxNorm normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg
Trial: NCT02309411
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
Trial: NCT01604928
Drug: YM178
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01604928
Drug: tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03469128
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline for the treatment of post-traumatic stress and SU disorders
Trial: NCT04392375
Drug: Nifedipine 30 MG
RxNorm normalized name: nifedipine 30 MG
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
Trial: NCT03620123
Drug: Nivolumab and Ipilimumab
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
Trial: NCT03620123
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m² intravenous infusion every three weeks
Trial: NCT01728818
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² d1,8,15 q4weeks
Trial: NCT01728818
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40mg flat dose, po, once daily
Trial: NCT01728818
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m², d1,8,15 q4weeks
Trial: NCT03619239
Drug: GX-I7
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
Trial: NCT00054938
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00054938
Drug: ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02161146
Drug: Vehicle to AGN-229666
RxNorm normalized name: AGN-201904
DrugBank: AGN-201904 (DB13135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
Trial: NCT02161146
Drug: Olopatadine
RxNorm normalized name: Olopatadine
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of olopatadine in the eye on Days 1 and 15.
Trial: NCT01847339
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
Trial: NCT01024868
Drug: Ropivacaine 0,5%
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
Trial: NCT03429933
Drug: BMS-986278
RxNorm normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02228733
Drug: KBP-5074
RxNorm normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparisons of different doses of study drug
Trial: NCT02453334
Drug: Injectafer
RxNorm normalized name: Injectafer
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02780726
Drug: roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT01704690
Drug: S-1 and Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
Trial: NCT01704690
Drug: Paclitaxel and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
Trial: NCT01704690
Drug: 5-FU and Cisplatin
RxNorm normalized name: 5-FU
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
Trial: NCT01868438
Drug: Pyronaridine-artesunate granules
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01868438
Drug: Pyronaridine-artesunate tablets
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00695292
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
Trial: NCT00695292
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC=4 on Day 1
Trial: NCT00695292
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib 25 mg orally (PO) daily after initial chemotherapy
Trial: NCT02497040
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local injection
Trial: NCT02497040
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local injection
Trial: NCT02954692
Drug: INSULIN GLARGINE (U300)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: pen for injection~Route of administration: subcutaneous
Trial: NCT02954692
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02954692
Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors
RxNorm normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT01177293
Drug: Amlodipine - reference
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine capsule, 10 mg, single dose, with water
Trial: NCT01177293
Drug: Amlodipine ODT - test
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
Trial: NCT00801203
Drug: IRCT
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Up to two administrations of the IRCT during a single cough testing session
Trial: NCT01876966
Drug: Etravirine
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
Trial: NCT01876966
Drug: Darunavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
Trial: NCT01876966
Drug: artemether/lumefantrine
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
Trial: NCT03918252
Drug: Nivolumab Injection
RxNorm normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
Trial: NCT00574470
Drug: daclizumab, infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
Trial: NCT00262132
Drug: Mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02448537
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00403897
Drug: Polyethylene glycol 3350 Na bicarbonate NaCl KCl
RxNorm normalized name: polyethylene glycol 3350 / potassium chloride / sodium bicarbonate / sodium chloride
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.9g sachet, oral
Trial: NCT03209622
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A
Trial: NCT03395080
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by IV infusion
Trial: NCT03395080
Drug: 300mg DKN-01
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT03395080
Drug: 600mg DKN-01
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT02175394
Drug: BI 1356
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03918252
Drug: Ipilimumab Injection
RxNorm normalized name: ipilimumab Injection
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
Trial: NCT02042326
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
Trial: NCT00845338
Drug: Darifenacin (BAY79-4998)
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days